logo
Sign in

Bo Yu

Principal investigator.

Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$9.5MFederal grants as PI30 awards
2Patents grantedLatest Jul 13, 2021
0PapersOpenAlex
Career record

Federal awards and patents by year

20152022
AwardsPatents
Federal awards as principal investigator

30 awards · $9.5M

DateAgencyAwardAmountCompany
Sep 30, 2022NIHSBIR Phase I
Pan-COVID Therapeutic Abstract Severe COVID-19
$276KLARIX BIOSCIENCE LLC
Sep 9, 2022NIHSBIR Phase I
PA21-259, PHS 2021-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical
$276KLARIX BIOSCIENCE LLC
Sep 1, 2022NIHSBIR Phase I
Advancing a novel therapy for preeclampsia
$385KLARIX BIOSCIENCE LLC
Aug 10, 2022NIHSBIR Phase I
Pan-COVID Therapeutic
$276KLARIX BIOSCIENCE LLC
Feb 22, 2022NIHSBIR Phase I
Therapeutic antibody for anorexia nervosa
$260KLARIX BIOSCIENCE LLC
Jul 13, 2021NIHSBIR Phase I
Therapeutic antibody for cancer-associated cachexia
$252KLARIX BIOSCIENCE LLC
Jul 1, 2021NIHSBIR Phase I
Novel therapy for myocardial ischemia-reperfusion injury
$252KLARIX BIOSCIENCE LLC
Jun 21, 2021NIHSBIR Phase I
Novel therapy for myocardial ischemia-reperfusion injury
$252KLARIX BIOSCIENCE LLC
Apr 10, 2021NIHSBIR Phase I
Inhibiting GPR146 in hypercholesterolemia
$250KLARIX BIOSCIENCE LLC
Sep 14, 2020NIHSBIR Phase I
Targeted Therapy for Type 1 diabetes
$250KLARIX BIOSCIENCE LLC
Sep 3, 2020NIHSBIR Phase I
Targeted therapeutic for Netherton syndrome
$252KLARIX BIOSCIENCE LLC
May 28, 2020NIHSBIR Phase I
Novel anti-fibrotic therapy for IPF
$225KLARIX BIOSCIENCE LLC
Sep 19, 2019NIHSBIR Phase I
Targeting TGF-beta activation in tumors
$225KLARIX BIOSCIENCE LLC
Sep 19, 2019NIHSBIR Phase I
Targeting TGF-beta activation in tumors
$225KLARIX BIOSCIENCE LLC
Aug 29, 2019NIHSBIR Phase I
Dual Intracellular and Extracellular Expression Technology (dIEE) for Parkinson’s Disease
$225KLARIX BIOSCIENCE LLC
Sep 21, 2018NIHSBIR Phase I
Dual Intracellular and Extracellular Expression Technology (dIEE) for Alzheimer’s Disease
$225KLARIX BIOSCIENCE LLC
Sep 18, 2018NIHSBIR Phase I
Novel GPCR-targeted therapy for preeclampsia
$225KLARIX BIOSCIENCE LLC
Sep 18, 2018NIHSBIR Phase I
Novel GPCR-targeted therapy for preeclampsia
$225KLARIX BIOSCIENCE LLC
Sep 13, 2018NIHSBIR Phase I
Targeting innate immunity in Type 1 diabetes
$225KLARIX BIOSCIENCE LLC
Sep 11, 2018NIHSBIR Phase II
Human glyco-engineered CHO cells
$789KLARIX BIOSCIENCE LLC
Dec 20, 2017NIHSBIR Phase I
Novel therapy for atopic dermatitis
$225KLARIX BIOSCIENCE LLC
Sep 20, 2017NIHSBIR Phase I
Novel therapy for Goodpasture syndrome
$224KLARIX BIOSCIENCE LLC
Sep 19, 2017NIHSBIR Phase I
Novel therapy for Goodpasture syndrome
$224KLARIX BIOSCIENCE LLC
Sep 1, 2017NIHSBIR Phase II
Human glyco-engineered CHO cells
$1.5MLARIX BIOSCIENCE LLC
Aug 22, 2017NIHSBIR Phase II
Human glyco-engineered CHO cells
$701KLARIX BIOSCIENCE LLC
Aug 11, 2017NIHSBIR Phase I
Novel monobody therapy for pancreatic cancer
$225KLARIX BIOSCIENCE LLC
Jun 1, 2017NIHSBIR Phase I
Novel targeted therapeutic for advanced metastatic disease
$225KLARIX BIOSCIENCE LLC
May 26, 2017NIHSBIR Phase I
Novel targeted therapeutic for advanced metastatic disease
$225KLARIX BIOSCIENCE LLC
Feb 1, 2015NIHSBIR Phase I
Human Glyco-engineered CHO Cells
$196KLARIX BIOSCIENCE LLC
Jan 26, 2015NIHSBIR Phase I
Human Glyco-engineered CHO Cells
$196KLARIX BIOSCIENCE LLC
Patents

3 patents as inventor

Matched by the first inventor’s name and the patent’s company.

Among 4,078 researchers in Biotech

Peer ranks

Federal funding#70
Awards as PI#5
Patents#102
From filings, awards and patents

Companies

Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.